Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2019-01-28273,2019,Malkin 2019 Diabetes Ther,620,Semaglutide (once-weekly 1mg) VERSUS Liraglutide 1.2mg IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Estonia; Other- Inadequate glycemic control on oral antidiabetic medications.,30535837,Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Estonia; Other- Inadequate glycemic control on oral antidiabetic medications.,Semaglutide (once-weekly 1mg),Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.,Liraglutide 1.2mg,NE
2017-01-24682,2017,Vorno 2017 Vaccine,14000,Nonavalent Human papillomavirus vaccine + cervical cancer screening VERSUS Cervical cancer screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.,28899625,Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.,Nonavalent Human papillomavirus vaccine + cervical cancer screening,Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.,Cervical cancer screening,NE
2017-01-24682,2017,Vorno 2017 Vaccine,17000,Bivalent Human papillomavirus vaccine + cervical cancer screening VERSUS Cervical cancer screening IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.,28899625,Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.,Bivalent Human papillomavirus vaccine + cervical cancer screening,Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.,Cervical cancer screening,NE
2017-01-24682,2017,Vorno 2017 Vaccine,17000,Quadrivalent Human papillomavirus vaccine + cervical cancer screening VERSUS Placebo IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.,28899625,Healthy; Age- 0 to 18 years; Gender- Female; Country- Estonia.,Quadrivalent Human papillomavirus vaccine + cervical cancer screening,Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.,Placebo,NE
2013-01-11597,2013,Uuskula 2013 BMC Infect Dis,7800,Routine vaccination VERSUS None IN Healthy; Age- Unknown; Gender- Female; Country- estonia.,23819789,Healthy; Age- Unknown; Gender- Female; Country- estonia.,Routine vaccination,The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia.,None,NE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
